The DOI matches its Crossref record; 467 of the 467 references it cites were found in a registry or an index.
RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges
Open accessAbstract
RNA-based therapies, including RNA molecules as drugs and RNA-targeted small molecules, offer unique opportunities to expand the range of therapeutic targets. Various forms of RNAs may be used to selectively act on proteins, transcripts, and genes that cannot be targeted by conventional small molecules or proteins. Although development of RNA drugs faces unparalleled challenges, many strategies have been developed to improve RNA metabolic stability and intracellular delivery. A number of RNA drugs have been approved for medical use, including aptamers (e.g., pegaptanib) that mechanistically act on protein target and small interfering RNAs (e.g., patisiran and givosiran) and antisense oligonucleotides (e.g., inotersen and golodirsen) that directly interfere with RNA targets. Furthermore, guide RNAs are essential components of novel gene editing modalities, and mRNA therapeutics are under development for protein replacement therapy or vaccination, including those against unprecedented severe acute respiratory syndrome coronavirus pandemic. Moreover, functional RNAs or RNA motifs are highly structured to form binding pockets or clefts that are accessible by small molecules. Many natural, semisynthetic, or synthetic antibiotics (e.g., aminoglycosides, tetracyclines, macrolides, oxazolidinones, and phenicols) can directly bind to ribosomal RNAs to achieve the inhibition of bacterial infections. Therefore, there is growing interest in developing RNA-targeted small-molecule drugs amenable to oral administration, and some (e.g., risdiplam and branaplam) have entered clinical trials. Here, we review the pharmacology of novel RNA drugs and RNA-targeted small-molecule medications, with a focus on recent progresses and strategies. Challenges in the development of novel druggable RNA entities and identification of viable RNA targets and selective small-molecule binders are discussed. SIGNIFICANCE STATEMENT: With the understanding of RNA functions and critical roles in diseases, as well as the development of RNA-related technologies, there is growing interest in developing novel RNA-based therapeutics. This comprehensive review presents pharmacology of both RNA drugs and RNA-targeted small-molecule medications, focusing on novel mechanisms of action, the most recent progress, and existing challenges.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 401–467 of 467
Bioengineering of noncoding RNAs for research agents and therapeutics
Ho, P. Y., & Yu, A. (2016) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1324 · Cited by 68
Self-citationWang, W., Ho, P. Y., Chen, Q., Addepalli, B., Limbach, P. A., Li, M., Wu, W., Jilek, J. L., Qiu, J., Zhang, H., et al. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.225631 · Cited by 67
Self-citationSequence determinants of innate immune activation by short interfering RNAs
Goodchild, A., Nopper, N., KING, A. G., Doan, T. B., Tanudji, M., Arndt, G. M., Poidinger, M., Rivory, L. P., & Passioura, T. (2009) · BMC Immunology · doi:10.1186/1471-2172-10-40 · Cited by 67
Eteplirsen Approved for Duchenne Muscular Dystrophy: The FDA Faces a Difficult Choice
Stein, C. A. (2016) · Molecular Therapy · doi:10.1038/mt.2016.188 · Cited by 67
Zhao, Y., Tu, M., Yu, Y.-F., Wang, W.-P., Chen, Q., Qiu, J.-X., Yu, A.-X., & Yu, A. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.10.015 · Cited by 66
Self-citationBioengineered Noncoding RNAs Selectively Change Cellular miRNome Profiles for Cancer Therapy
Ho, P. Y., Duan, Z., Batra, N., Jilek, J. L., Tu, M., Qiu, J.-X., Hu, Z., Wun, T., Lara, P. N., White, R. D., et al. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.247775 · Cited by 66
Self-citationRamot, Y., Rotkopf, S., Gabai, R. M., Zorde Khvalevsky, E., Muravnik, S., Marzoli, G. A., Domb, A. J., Shemi, A., & Nyska, A. (2016) · Toxicologic Pathology · doi:10.1177/0192623316645860 · Cited by 64
Li, P., Tu, M., Ho, P. Y., Jilek, J. L., Duan, Z., Zhang, Q.-Y., Yu, A., & Yu, A. (2017) · Drug Metabolism and Disposition · doi:10.1124/dmd.117.078741 · Cited by 63
Self-citationGermline transgenesis in rodents by pronuclear microinjection of Sleeping Beauty transposons
Ivics, Z., Mátés, L., Yau, T. Y., Landa, V., Zı́dek, V., Bashir, S., Hoffmann, O. I., Hiripi, L., Garrels, W., Kues, W. A., et al. (2014) · Nature Protocols · doi:10.1038/nprot.2014.008 · Cited by 63
SDF-1 Blockade Enhances Anti-VEGF Therapy of Glioblastoma and Can Be Monitored by MRI
Deng, L., Stafford, J. H., Liu, S.-C., Chernikova, S. B., Merchant, M. J., Recht, L. D., & Brown, J. M. (2016) · Neoplasia · doi:10.1016/j.neo.2016.11.010 · Cited by 62
Husser, C., Brink, A., Zell, M., Müller, M. B., Koller, E., & Schadt, S. (2017) · Analytical Chemistry · doi:10.1021/acs.analchem.7b01244 · Cited by 62
Ethical Challenges Confronted When Providing Nusinersen Treatment for Spinal Muscular Atrophy
Burgart, A. M., Magnus, D. C., Tabor, H. K., Paquette, E., Frader, J. E., Glover, J. J., Jackson, B. M., Harrison, C. H., Urion, D. K., Graham, R. J., et al. (2017) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2017.4409 · Cited by 62
Insights into the development of chemical probes for RNA
Morgan, B. S., Forte, J. E., & Hargrove, A. E. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky718 · Cited by 61
Li, M.-M., Addepalli, B., Tu, M., Chen, Q., Wang, W.-P., Limbach, P. A., LaSalle, J. M., Zeng, S., Huang, M., & Yu, A. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.064493 · Cited by 59
Self-citationGeneration of targeted mouse mutants by embryo microinjection of TALEN mRNA
Wefers, B., Panda, S. K., Ortiz, O., Brandl, C., Hensler, S., Hansen, J., Wurst, W., & Kühn, R. (2013) · Nature Protocols · doi:10.1038/nprot.2013.142 · Cited by 58
The siRNA sequence and guide strand overhangs are determinants of in vivo duration of silencing
Strapps, W. R., Pickering, V., Muiru, G. T., Rice, J., Orsborn, S., Polisky, B. A., Sachs, A. B., & Bartz, S. R. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq206 · Cited by 58
Zhang, X., Lai, M., Chang, W. Y.-H., Yu, I., Ding, K., Mrazek, J., Ng, H. L., Yang, O. O., Maslov, D. A., & Zhou, Z. (2016) · Nature Communications · doi:10.1038/ncomms13223 · Cited by 58
Condon, T. P., & Bennett, C. F. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.48.30398 · Cited by 57
RNA quaternary structure and global symmetry
Jones, C. P., & Ferré-D’Amaré, A. R. (2015) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2015.02.004 · Cited by 56
Post-transcriptional inducible gene regulation by natural antisense RNA
Nishizawa, M. (2015) · Frontiers in bioscience · doi:10.2741/4297 · Cited by 56
Post, N. M., Yu, R. Z., Greenlee, S., Gaus, H. J., Hurh, E., Matson, J. E., & Wang, Y. (2019) · Drug Metabolism and Disposition · doi:10.1124/dmd.119.087395 · Cited by 55
Ion exchange liquid chromatography method for the direct determination of small ribonucleic acids
McGinnis, A. C., Cummings, B. S., & Bartlett, M. G. (2013) · Analytica Chimica Acta · doi:10.1016/j.aca.2013.08.040 · Cited by 53
Ewles, M., Goodwin, L., Schneider, A., & Rothhammer-Hampl, T. (2014) · Bioanalysis · doi:10.4155/bio.13.319 · Cited by 53
The Apical Loop of the HIV-1 TAR RNA Hairpin Is Stabilized by a Cross-loop Base Pair
Kuliński, T., Olejniczak, M., Huthoff, H., Bielecki, Ł., Pachulska‐Wieczorek, K., Das, A. T., Berkhout, B., & Adamiak, R. W. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301939200 · Cited by 52
Tu, M., Ho, P. Y., Zhang, Q.-Y., Jian, C., Qiu, J.-X., Kim, E. J.-H., Bold, R. J., Gonzalez, F. J., Bi, H., & Yu, A. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.10.038 · Cited by 52
Self-citationde Jong, W., Aerts, J. L., Allard, S. D., Brander, C., Buyze, J., Florence, É., Gorp, E. C. M. V., Vanham, G. L., Leal, L., Mothe, B., et al. (2019) · Trials · doi:10.1186/s13063-019-3409-1 · Cited by 52
Invention and Early History of Morpholinos: From Pipe Dream to Practical Products
Summerton, J. E. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-6817-6_1 · Cited by 51
Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing's Sarcoma
Rao, D. D., Jay, C. M., Wang, Z., Luo, X., Kumar, P., Eysenbach, H., Ghisoli, M. L., Senzer, N. N., & Nemunaitis, J. J. (2016) · Molecular Therapy · doi:10.1038/mt.2016.93 · Cited by 50
Structural Characterization of an Alternative Mode of Tigecycline Binding to the Bacterial Ribosome
Schedlbauer, A., Kaminishi, T., Ochoa-Lizarralde, B., Dhimole, N., Zhou, S., López-Alonso, J. P., Connell, S. R., & Fucini, P. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04895-14 · Cited by 49
Tamar Schlick, A. (2018) · Methods · doi:10.1016/j.ymeth.2018.03.009 · Cited by 49
Application of Locked Nucleic Acid Oligonucleotides for siRNA Preclinical Bioanalytics
Thayer, M. B., Lade, J. M., Doherty, D. R., Xie, F., Basiri, B., Barnaby, O. S., Bala, N. S., & Rock, B. M. (2019) · Scientific Reports · doi:10.1038/s41598-019-40187-4 · Cited by 47
Xu, J., Sun, J., Ho, P. Y., Luo, Z., Ma, W., Zhao, W., Rathod, S., Fernandez, C. A., Venkataramanan, R., Xie, W., et al. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.04.025 · Cited by 47
Self-citationCRISPR/Cas System for Genome Editing: Progress and Prospects as a Therapeutic Tool
Sahel, D. K., Mittal, A., & Chitkara, D. (2019) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.257287 · Cited by 47
Advances in Quantitative Bioanalysis of Oligonucleotide Biomarkers and Therapeutics
Wang, L., & Ji, C. (2015) · Bioanalysis · doi:10.4155/bio.15.234 · Cited by 46
Zhang, Q.-Y., Ho, P. Y., Tu, M., Jilek, J. L., Chen, Q., Zeng, S., & Yu, A.-M. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.06.026 · Cited by 46
Self-citationPopplewell, L. J., Adkin, C. F., Arechavala‐Gomeza, V., Aartsma-Rus, A. M., de Winter, C. L., Wilton, S. D., Morgan, J. E., Francesco Muntoni, A., Graham, I. R., & Dickson, G. (2010) · Neuromuscular Disorders · doi:10.1016/j.nmd.2009.10.013 · Cited by 45
Green, K. M., Sheth, U., Flores, B. N., Wright, S. E., Sutter, A. B., Kearse, M. G., Barmada, S. J., Ivanova, M. I., & Todd, P. K. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.009951 · Cited by 45
Kobayashi, H., Eckhardt, S. G., Lockridge, J. A., Rothenberg, M. L., Sandler, A., O’Bryant, C. L., Cooper, W., Holden, S. N., Aitchison, R., Usman, N., et al. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0968-x · Cited by 44
Zhao, Y., Tu, M., Wang, W.-P., Qiu, J.-X., Yu, A.-X., & Yu, A. (2016) · Scientific Reports · doi:10.1038/srep26611 · Cited by 44
Self-citationQurashi, A., Liu, H., Ray, L., Nelson, D. L., Duan, R., & Jin, P. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds024 · Cited by 42
Jilek, J. L., Zhang, Q.-Y., Tu, M., Ho, P. Y., Duan, Z., Qiu, J., & Yu, A. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.01.007 · Cited by 39
Self-citationLiu, J., Li, J., Tran, C., et al. (2019) · Bioanalysis · doi:10.4155/bio-2019-0137 · Cited by 39
Targeting the HIV RNA Genome: High-Hanging Fruit Only Needs a Longer Ladder
Grice, S. F. J. L. (2015) · Current topics in microbiology and immunology · doi:10.1007/82_2015_434 · Cited by 38
Li, M.-M., Wang, W.-P., Wu, W.-J., Huang, M., & Yu, A. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.060145 · Cited by 37
Self-citationA transposon-derived small RNA regulates gene expression in Salmonella Typhimurium
Ellis, M. J., Trussler, R. S., Charles, O., & Haniford, D. B. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx094 · Cited by 35
Li, J., Nakamori, M., Matsumoto, J., Murata, A., Dohno, C., Kiliszek, A., Taylor, K., Sobczak, K., & Nakatani, K. (2018) · Chemistry - A European Journal · doi:10.1002/chem.201804368 · Cited by 35
Regulatory aspects of drug approval for macular degeneration
Gryziewicz, L. J. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2005.09.009 · Cited by 34
Novel approaches for efficient in vivo fermentation production of noncoding RNAs
Yu, A., Batra, N., Tu, M., & Sweeney, C. A. (2020) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-020-10350-3 · Cited by 34
Self-citationHeiser, A., Coleman, D., Dannull, J., Yancey, D. R., Maurice, M. A., Lallas, C. D., Dahm, P., Niedzwiecki, D., Gilboa, E., & Vieweg, J. (2002) · Journal of Clinical Investigation · doi:10.1172/jci200214364 · Cited by 33
Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis
Coelho, T., Yarlas, A. S., Waddington‐Cruz, M., White, M. K., Kessler, A. S., Lovley, A., Pollock, M. R., Guthrie, S. D., Ackermann, E. J., Hughes, S. G., et al. (2019) · Journal of Neurology · doi:10.1007/s00415-019-09671-9 · Cited by 32
Watanabe, A., Nakajima, M., Kasuya, T., Onishi, R., Kitade, N., Mayumi, K., Ikehara, T., & Kugimiya, A. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.230300 · Cited by 31
Bioengineering of a single long noncoding RNA molecule that carries multiple small RNAs
Petrek, H. E., Batra, N., Ho, P. Y., Tu, M., & Yu, A. (2019) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-019-09934-5 · Cited by 31
Self-citationJian, C., Tu, M., Ho, P. Y., Duan, Z., Zhang, Q., Qiu, J.-X., White, R. D., Wun, T., Lara, P. N., Lam, K. S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16372 · Cited by 30
Self-citationHashiro, S., Mitsuhashi, M., Chikami, Y., Kawaguchi, H., Niimi, T., & Yasueda, H. (2019) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-019-10113-9 · Cited by 30
Plasma and Liver Protein Binding of N-Acetylgalactosamine–Conjugated Small Interfering RNA
Humphreys, S. C., Thayer, M. B., Lade, J. M., Wu, B., Sham, K. K. C., Basiri, B., Hao, Y., Huang, X., Smith, R. J., & Rock, B. M. (2019) · Drug Metabolism and Disposition · doi:10.1124/dmd.119.086967 · Cited by 29
Bioavailable inhibitors of HIV-1 RNA biogenesis identified through a Rev-based screen
Prado, S., Beltrán, M., Coiras, M., Bedoya, L. M., Alcamı́, J., & Gallego, J. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.02.007 · Cited by 28
Pharmacokinetic and Drug Metabolism Properties of Novel Therapeutic Modalities
Rock, B. M., & Foti, R. (2019) · Drug Metabolism and Disposition · doi:10.1124/dmd.119.088708 · Cited by 26
Mapping of the second tetracycline binding site on the ribosomal small subunit of E.coli
Anokhina, M. M., Barta, A., Nierhaus, K. H., Spiridonova, V. A., & Kopylov, A. M. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh583 · Cited by 25
Simoens, S., & Huys, I. (2017) · Gene Therapy · doi:10.1038/gt.2017.79 · Cited by 20
mRNA Vaccines: Possible Tools to Combat SARS-CoV-2
Yi, C., Yi, Y., & Li, J. (2020) · Virologica Sinica · doi:10.1007/s12250-020-00243-0 · Cited by 20
Kim, H. S., Lee, H. S., & Kim, W. H. (2012) · Cancer Research · doi:10.1158/1538-7445.am2012-5576 · Cited by 18
Age-related macular degeneration: experimental and emerging treatments
Hubschman, J., Reddy, S., & Schwartz, S. D. (2009) · Clinical ophthalmology · doi:10.2147/opth.s5156 · Cited by 17
Hashiro, S., Mitsuhashi, M., & Yasueda, H. (2019) · Journal of Bioscience and Bioengineering · doi:10.1016/j.jbiosc.2019.03.003 · Cited by 16
Huang, X., Zhang, H., Wang, H., Xiong, K., Qin, L., & Liu, H. (2014) · Molecules and Cells · doi:10.14348/molcells.2014.2209 · Cited by 11
Developing Therapies for Age-related Macular Degeneration: The Art and Science of Problem-solving
Miller, J. W. (2019) · Ophthalmology Retina · doi:10.1016/j.oret.2019.07.015 · Cited by 11
GRK5-Knockout Mice Generated by TALEN-Mediated Gene Targeting
Nanjidsuren, T., Park, C., Sim, B., Kim, S., Chang, K., Kang, M., & Min, K. (2016) · Animal Biotechnology · doi:10.1080/10495398.2016.1176032 · Cited by 6
Hoerr, I. (2000) · doi:10.1002/1521-4141(200001)30:1
Cited by
Molecular photoswitches in aqueous environments
Volarić, J., Szymanski, W., Simeth, N. A., & Feringa, B. L. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00547a · Cited by 438
Delivery of oligonucleotide‐based therapeutics: challenges and opportunities
Hammond, S. M., Aartsma‐Rus, A., Alves, S., Borgos, S. E., Buijsen, R. A. M., Collin, R. W. J., Covello, G., Denti, M. A., Desviat, L. R., Echevarría, L., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202013243 · Cited by 388
RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies
Traber, G. M., & Yu, A.-M. (2023) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.122.001234 · Cited by 291
Self-citationMicroRNA as an Important Target for Anticancer Drug Development
Fu, Z., Wang, L., Li, S., Chen, F., Au-Yeung, K. K.-W., & Shi, C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.736323 · Cited by 133
An ontology-based knowledge graph for representing interactions involving RNA molecules
Cavalleri, E., Cabri, A., Soto-Gomez, M., Bonfitto, S., Perlasca, P., Gliozzo, J., Callahan, T. J., Reese, J., Robinson, P. N., Casiraghi, E., et al. (2024) · Scientific Data · doi:10.1038/s41597-024-03673-7 · Cited by 33
Metadata
- Authors
- Yu, A.-M., Choi, Y. H., & Tu, M.-J.
- Venue
- Pharmacological Reviews
- Publisher
- Elsevier BV
- Published
- 2020-10
- Volume
- 72
- Issue
- 4
- Pages
- 862-898
- ISSN
- 0031-6997 (ISSN-L)
- OpenAlex
- W3084513853
- Cited by
- 395
- References
- 467
- FWCI
- 13.14
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.